Interstitial Cystitis - Few Treatments, Poor Outcome

Questions: Discounts, Updates etc.

Price: $7,600.00

Publication Date: 2006-04-14

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Interstitial cystitis (IC) is considered a rare disorder and poor understanding of the underlying causes of the disorder have made diagnosis and management difficult. Moreover, this has impacted on the development of effective drugs for this disorderthere are few available treatments for IC and as a result, significant unmet needs exist.


Scope

  • Quantitative treatment data from 190 physicians based in US, Japan, France, Germany, Italy, Spain and UK; supported by key opinion leader comments
  • Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and first- to second-line treatments for IC
  • Influences on treatment choice and perception of current drug therapies including pentosan polysulfate sodium and the antimuscarinics
  • Influences on treatment choice and perception of current drug therapies, unmet needs and future outlook including the R&D drug pipeline


    • Report Highlights
    Presentation rates for IC are higher than in other OAB disorders due to the patient experience of pain. However, discord in the terminology and diagnostic criteria for IC confound diagnosis; and as result, the diagnosis of IC tends to be one of exclusion, and as such can take many years to be reached, bringing unnecessary suffering to the patient.

    IC symptoms have a similar terminology to those of Overactive Bladder, but are fundamentally different. Poor understanding of the disorder and limited treatment options means that many physicians have resorted to using antimuscarinics despite their limited proven efficacy in treating the pain.

    Further research into the etiology of IC is the key to finding a truly effective treatment for IC that works. In the meantime, companies wishing to target the IC market should aim to demonstrate the ability of their drug to treat pain in addition to urgency and frequency.


    Reasons to Purchase

  • Forecast product sales by understanding key aspects of IC epidemiology, diagnosis and treatment
  • Gain a better understanding of the challenges facing current and future players in the IC market
  • Identify physicians key concerns in IC including unmet needs and the attributes that physicians believe are desirable for future treatments

    • Table of Contents

    Other users found this report page using the following search terms: cystitis

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.